Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Why did I suspect, the newest Director, William L. Ashton, worked at Amgen prior to reading the PR? Just rocket science I guess.

Feb 27, 2018
Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its Board of Directors
HENDERSON, Nev.--(BUSINESS WIRE)--Feb. 27, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the appointment of William L. Ashton to its board of directors, effective February 23, 2018. The appointment will increase the size of the Board of Directors to nine members.
“Bill is an accomplished industry leader with a diverse background which will help us navigate our next phase of growth,” said Joseph W. Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. “His experience with government affairs, healthcare legislation, private payers and working with key agencies will help our Company realize the commercial potential of our promising late-stage assets. We believe his strong expertise in the biotechnology and pharmaceutical business will be extremely valuable addition to the Spectrum board.”
“I am honored to join the Board of Directors at this exciting and transformative time in Spectrum’s history,” said William L. Ashton. “I look forward to contributing to Spectrum’s future growth and success as the Company executes several late-stage development activities with the potential to change patients’ lives.”
William Ashton is a former Fortune 100 senior executive with over 40 years’ experience in the biotechnology and pharmaceutical business. Mr. Ashton has retired from an extensive career at Amgen Inc. While with Amgen he served in various positions including Vice President of U.S. Sales for Amgen. He also served as Vice President/General Manager of the Corporate Accounts, Business Unit. This unit has responsibility for the sales and marketing to Amgen's largest customer base including health systems, managed care organizations, commercial and government payers, distribution channels, GPO’s and the corporate pricing group.
Since the beginning of 2013, Mr. Ashton has been a principal at Harrison Consulting Group, LLC, a privately held biopharmaceutical consulting firm with expertise in commercialization, payer strategy, and reimbursement.
Mr. Ashton currently serves on the board of Recro Pharma, a publicly traded company. He has previously served on the boards of publicly traded companies, Sucampo Pharmaceuticals and Galena Bio Pharma. He received his Bachelor of Science from California University of Pennsylvania and his Master of Science from the University of Pittsburgh.

http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-appointment-william-l-ashton

Having a buddy on board will help JT in moving this ship to where he wants it to go.